S&CO Inc. Has $6 Million Position in Edwards Lifesciences Corporation (NYSE:EW)

S&CO Inc. boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 34.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 82,797 shares of the medical research company’s stock after acquiring an additional 21,115 shares during the quarter. S&CO Inc.’s holdings in Edwards Lifesciences were worth $6,001,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Vega Investment Solutions acquired a new stake in Edwards Lifesciences in the 4th quarter worth approximately $27,000. Global X Japan Co. Ltd. lifted its stake in shares of Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock worth $29,000 after buying an additional 216 shares during the last quarter. Tradewinds Capital Management LLC boosted its holdings in shares of Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock worth $29,000 after buying an additional 205 shares during the period. Rossby Financial LCC acquired a new position in Edwards Lifesciences in the 1st quarter valued at $29,000. Finally, ORG Wealth Partners LLC bought a new position in Edwards Lifesciences in the 1st quarter worth $38,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 1.9%

Shares of EW opened at $78.46 on Tuesday. The stock has a 50 day simple moving average of $76.58 and a 200-day simple moving average of $73.59. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The stock has a market cap of $46.02 billion, a PE ratio of 11.29, a PEG ratio of 4.00 and a beta of 1.11. Edwards Lifesciences Corporation has a 1 year low of $59.41 and a 1 year high of $83.00.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.25% and a net margin of 72.96%. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.70 earnings per share. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on EW. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a report on Friday. Morgan Stanley increased their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Dbs Bank raised Edwards Lifesciences to a “hold” rating in a report on Monday, June 2nd. Canaccord Genuity Group upped their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a report on Friday. Finally, Stifel Nicolaus increased their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.00.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $74.40, for a total value of $837,000.00. Following the transaction, the chief financial officer directly owned 41,098 shares in the company, valued at $3,057,691.20. The trade was a 21.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bernard J. Zovighian sold 5,980 shares of the firm’s stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $74.91, for a total transaction of $447,961.80. Following the sale, the chief executive officer directly owned 58,284 shares of the company’s stock, valued at approximately $4,366,054.44. The trade was a 9.31% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,962 shares of company stock worth $2,641,387 over the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.